Changing landscape
for PD-L1-high NSCLC treatments
Speakers: Dr Ross Soo
(Singapore, Moderator), Dr Mark Socinski (US, Speaker), Dr Roy Herbst (US,
Speaker), Dr Yuh Min Chen (Taiwan, Speaker)
Objective: Offer opportunity
for therapeutic area expert to share knowledge and deliver updated scientific
information in the area of PD-L1-high NSCLC treatments
What are the treatments available for PD-L1-high population
What are some of the
diagnostics in determining PD-L1-high status? Is there any difference?
Future Directions for PD-L1-high NSCLC
treatments
Patient Case Study: PD-L1-high patient on Tecentriq
monotherapy, using 22C3 testing
Patient Case Study: PD-L1-high patient on Tecentriq combination therapy